Table 2.

Progression of preneoplastic lesions

% Normal epithelium or preneoplastic esophageal lesions (± SE)
GroupNMBA (0.35 mg/kg)Diet administeredNormalEpithelial hyperplasiaLow-grade dysplasiaHigh-grade dysplasia
Week 15
 1AIN-76A98.5a (3.1)1.5a (3.1)00
 2+AIN-76A53.2 (21.6)39.4 (16.2)7.1 (9.2)0.3 (0.2)
 3+6.1% BRB96.2a (4.2)3.2a (3.5)0.6 (1.7)0
 4+3.8 μmol ACs/g92.7a (10.9)6.9a (10.6)0.4 (1.3)0
 5+500 ppm PCA86.9a (12.7)10.2a (10.4)2.5 (3.3)0.4 (0.1)
Week 25
 1AIN-76A86.2a (1.2)13.8a (1.2)00
 2+AIN-76A51.4 (3.2)20.7 (2.0)13.4 (0.4)14.5 (0.5)
 3+6.1% BRB52.9 (2.9)25.3 (1.4)16.0 (1.6)5.8a (0.8)
 4+3.8 μmol ACs/g56.7 (1.3)25.1 (0.7)13.9 (0.5)4.3a (0.4)
 5+500 ppm PCA57.7 (2.0)26.7 (1.1)11.2 (0.8)4.4a (0.5)
Week 35
 1AIN-76A93.6a (0.8)6.2a (0.5)4.7a (0.5)0
 2+AIN-76A31.6 (0.5)22.4 (0.7)21.3 (0.6)24.7 (0.5)
 3+6.1% BRB51.3a (1.1)22.4 (0.5)15.2a (0.8)11.1a (0.5)
 4+3.8 μmol ACs/g53.4a (1.2)21.0 (0.7)16.0a (0.6)9.6a (0.7)
 5+500 ppm PCA50.5a (1.4)25.3 (0.7)16.6a (0.8)7.7a (0.4)

NOTE: BRB, AC, and PCA diets were mixed with AIN-76A.

  • aStatistically significant relative to NMBA controls (group 2; P < 0.05).